» Articles » PMID: 20002475

Abnormal Liver Function Tests in Patients with Type 1 Diabetes Mellitus: Prevalence, Clinical Correlations and Underlying Pathologies

Overview
Journal Diabet Med
Specialty Endocrinology
Date 2009 Dec 17
PMID 20002475
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

Aims: To determine the prevalence of elevated alanine transaminase (ALT) in a large cohort of patients with Type 1 diabetes and to examine the clinical correlations and causes. Methods Patients with Type 1 diabetes mellitus were prospectively recruited and ALT, glycated haemoglobin and lipid profile were measured. Patients with Type 2 diabetes mellitus were recruited as a comparison group.

Patients: with abnormal ALT were investigated for underlying causes. Prevalence of abnormal ALT was analysed at three separate cut-offs and multivariable analysis used to identify independent risk factors.

Results: Nine hundred and eleven with Type 1 diabetes and 963 with Type 2 diabetes were included. The prevalence of elevated ALT was dependent on the cut-off value: > 30 IU/l in males and > 19 IU/l in females, > 50 and > 63 IU/l was 34.5, 4.3 and 1.9%, respectively, in Type 1 diabetes and 51.4, 8.2 and 3.7%, respectively, in Type 2 diabetes. In Type 1 diabetes an elevated ALT was associated with worse glycaemic control, age > 55 years and elevated triglycerides. Investigation of these patients revealed a cause in 43.6% of patients, predominantly non-alcoholic fatty liver disease (NAFLD).

Conclusions: Elevated ALT is not uncommon in Type 1 diabetes and is associated with NAFLD-related risk factors. Patients with Type 1 diabetes and elevated ALT should be investigated as significant abnormalities may be found which are amenable to interventions.

Citing Articles

Longitudinal Analysis of Bone Metabolic Markers and Bone Mechanical Properties in STZ-Induced Diabetic Rats.

Tomaszewska E, Dobrowolski P, Muszynski S, Donaldson J, Golynski M, Zwolska J J Clin Med. 2024; 13(18).

PMID: 39337082 PMC: 11433195. DOI: 10.3390/jcm13185595.


Group-informed attentive framework for enhanced diabetes mellitus progression prediction.

Sheng C, Wang L, Long C, Yue R Front Endocrinol (Lausanne). 2024; 15:1388103.

PMID: 38978615 PMC: 11228145. DOI: 10.3389/fendo.2024.1388103.


Polyester Nanoparticles with Controlled Topography for Peroral Drug Delivery Using Insulin as a Model Protein.

Heyns I, Arora M, Ganugula R, Allamreddy S, Tiwari S, Shah D ACS Nano. 2024; 18(18):11863-11875.

PMID: 38622996 PMC: 11145941. DOI: 10.1021/acsnano.4c01027.


Supplementation Restores Normoglycemia, Corrects Dyslipidemia, and Transcriptionally Modulates Pancreatic and Hepatic Gene Expression in Alloxan-Induced Hyperglycemic Rats.

Muzaffar H, Qamar I, Bashir M, Jabeen F, Irfan S, Anwar H Metabolites. 2023; 13(4).

PMID: 37110174 PMC: 10142569. DOI: 10.3390/metabo13040516.


Non-alcoholic fatty liver disease in type 1 diabetes: Prevalence and pathophysiology.

Memaj P, Jornayvaz F Front Endocrinol (Lausanne). 2022; 13:1031633.

PMID: 36531463 PMC: 9752856. DOI: 10.3389/fendo.2022.1031633.